Antimicrobial bacterial resistance, a persistent threat

2019, Number 2

Enf Infec Microbiol 2019; 39 (2)

Miranda NMG

Language: Spanish
References: 6
Page: 47-48
PDF size: 166.48 Kb.

Text Extraction

No abstract.

REFERENCES

Pendleton JN, Gorman SP, Gilmore BF. Clinical Relevance of the ESKAPE pathogens. Expert Rev Anti Infect Ther. 2013;11(3):297-308.
Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis. Geneva: World Health Organization; 2017(WHO/EMP/IAU/2017.12)
Mulani MS, Kamble EE, Kumkar SN, Tawre MS, Pardesi KR. Emerging Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial Resistance: A Review. Front Microbiol. 2019 Apr 1;10:539.
Centers for Disease Control and Prevention. Antibiotic / Antimicrobial Resistance. Biggest Threats.https://www. cdc.gov/drugresistance/biggest_threats.html (fecha de acceso mayo 30, 2019).
Centers for Disease Control and Prevention. About antimicrobial resistance 2018. https://www.cdc.gov/drugresistance/ about.html (fecha de acceso mayo 30, 2019).
Kadri S, Adjemian J Lai YL, Spaulding AB, Ricotta E, Prevots DR et al. Difficult-to-Treat Resistance in Gramnegative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents. Clin Infect Dis. 2018 Nov 28;67(12):1803-1814.